Clinical trials: Heart Failure, Acute
Dyspnea, Acute Heart Failure Syndrome
Precision of IMED-4 Lung Fluid Measurements
The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary congestion.
- Conditions
- Dyspnea, Acute Heart Failure Syndrome, Pulmonary Congestion
- Trial name
- NCT02187770
- Testing
- IMED-4
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Intersection Medical, Inc.
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 1 (NCT00525707)
- Testing
- tezosentan
- Where
- 35 sites in United States, Austria and 8 more
- Volunteers
- 735 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acute Myocardial Infarction, Pacing Therapy
Post-Myocardial Infarction Remodeling Prevention Therapy
The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial…
- Conditions
- Acute Myocardial Infarction, Pacing Therapy, Cardiac Remodeling, Heart Failure
- Trial name
- PRomPT (NCT01213251)
- Testing
- Single Site Pacing, Dual Site Pacing
- Where
- 26 sites in United States, Denmark and 5 more
- Volunteers
- 129 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Dyspnea, Acute Decompensated Heart Failure
Evaluation of Cardiopulmonary Diseases by Ultrasound
Historically, ultrasound imaging of the lung parenchyma has been challenging because of the high total ultrasound energy attenuation and scattering by the air in the lungs.
- Trial name
- NCT02248831
- Testing
- Recording Doppler ultrasound signals noninvasively
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Echosense Ltd.
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Congestive Heart Failure
Ultrafiltration Versus Intravenous (IV) Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: (UNLOAD)
The purpose of this study is to compare patients who are suffering from heart failure and who are fluid overloaded to determine if ultrafiltration (UF) can remove more of the extra fluid as measured by weight loss while in the…
- Trial name
- NCT00124137
- Testing
- Aquadex system, IV diuretic
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Nuwellis, Inc.
Heart Failure, Congestive
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow…
- Trial name
- NCT00357591
- Testing
- Continuous Aortic Flow Augmentation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Orqis Medical Corporation
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Heart Decompensation, Acute
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is no formal hypothesis to be statistically tested.
- Trial name
- NCT02932969
- Testing
- BMS-986231
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Kidney Injury, Renal Insufficiency
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Kidney Diseases
- Trial name
- NORDICA (NCT02263820)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Sapere Bio
Acute Decompensated Heart Failure
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure
The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.
- Trial name
- NCT00839007
- Testing
- CD-NP
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 77 people
- Sponsor
- Nile Therapeutics
Acute Decompensated Heart Failure
Safety and Performance Evaluation of the Nephronyx System for the Treatment of Patients With ADHF
The objective of this interventional study is to evaluate the safety and functional performance of the Nephronyx System in patients with ADHF, presenting clinical signs of volume overload and compromised response to diuretics.
- Trial name
- NCT05759806
- Testing
- Nephronyx system (Perfuser)
- Where
- 4 sites in Israel
- Volunteers
- 10 people
- Sponsor
- Nephronyx LTD
Acute Decompensated Heart Failure
Reprieve System Pilot Study
The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure.
- Trial name
- NCT06272734
- Testing
- Reprieve System
- Where
- Georgia
- Volunteers
- 50 people
- Sponsor
- Reprieve Cardiovascular, Inc
Heart Failure, Congestive, Heart Decompensation
Longitudinal Registry for Advanced Heart Failure Patients
The purpose of this study is to gather information to better understand the characteristics, medical management techniques and outcomes of patients with chronic severe Heart Failure (HF).
- Trial name
- NCT00364416
- Testing
- Any treatment used to treat CHF
- Volunteers
- 1,466 people
- Sponsor
- Scios, Inc.
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.